These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 22253234)

  • 21. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
    Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
    Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adult form of Pompe disease].
    Ziółkowska-Graca B; Kania A; Zwolińska G; Nizankowska-Mogilnicka E
    Pneumonol Alergol Pol; 2008; 76(5):396-9. PubMed ID: 19003770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.
    Castellar-Leones SM; Ortiz-Corredor F; Manrique-Hernández D; Sánchez-Peñarete D; Ruiz-Ospina E; Soto-Peña D; Correa-Arrieta C
    J Med Case Rep; 2024 Jul; 18(1):328. PubMed ID: 39020349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulatory, liver depot gene therapy for Pompe disease.
    Bond JE; Kishnani PS; Koeberl DD
    Cell Immunol; 2019 Aug; 342():103737. PubMed ID: 29295737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
    J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
    Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
    Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme.
    Pascual SI
    Adv Exp Med Biol; 2009; 652():39-46. PubMed ID: 20225018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
    Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
    Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.